Skip to Content

SPDR® S&P Pharmaceuticals ETF XPH

Medalist Rating as of | See State Street Investment Hub

Morningstar’s Analysis XPH

Will XPH outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

SPDR ® S&P Pharmaceuticals ETF’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings XPH

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 40.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Intra-Cellular Therapies Inc

4.32 8.5 Mil
Healthcare

Axsome Therapeutics Inc

4.30 8.5 Mil
Healthcare

Viatris Inc

4.12 8.1 Mil
Healthcare

Eli Lilly and Co

3.98 7.9 Mil
Healthcare

Catalent Inc

3.92 7.7 Mil
Healthcare

Zoetis Inc Class A

3.90 7.7 Mil
Healthcare

Pfizer Inc

3.89 7.7 Mil
Healthcare

Perrigo Co PLC

3.88 7.7 Mil
Healthcare

Johnson & Johnson

3.85 7.6 Mil
Healthcare

Organon & Co Ordinary Shares

3.83 7.6 Mil
Healthcare